» Articles » PMID: 38357318

Drug Utilization Studies in Turkiye: A Systematic Review

Overview
Publisher Kare Publishing
Specialty General Medicine
Date 2024 Feb 15
PMID 38357318
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Drug utilization studies (DUS) provide a framework for drug utilization at the national or targeted population level and important information on unmet medical needs, particularly in assessing the rationality of drug use. We aimed to systematically review DUS conducted in Turkiye.

Methods: We examined 162 DUS with an accessible full-text, published as "research articles" and conducted in Turkiye between 2000 and 2021 using medical records and prescription data. We included English or Turkish papers with English abstracts. We examined the scientific characteristics of the publications, source of the data, place/time of collection, research designs, and studied drug groups.

Results: We found that 79.6% of articles were in English, 45.1% were listed in SCI/SCIE, and 63.0% were on the WOS platform with 3.5 (interquartile range: 1-15) citations. The mean study period and publication time were 2.9±3.1 and 2.9±2.1 years, respectively. The highest number of studies (17.9%) were published in 2021 and (26.5%) were conducted nationwide. We identified that 93.8% of the studies had retrospective design, 67.8% were conducted in secondary/tertiary health-care institutions, and 54.9% used direct hospital data. We detected that 68.5% of the studies were conducted on the general population, 19.1% on adults, 12.4% on children, and 44.4% were antibiotic oriented.

Conclusion: Our study showed that a significant portion of the DUS, the trend of which has gained momentum in recent years, was antibiotic focused and conducted with a retrospective design from hospital-based data collected on the general patient population. This situation points to the necessity of expanding the existing DUS range by effectively using the new advantages provided by medical record databases and conducting more DUS that can provide critical clues for specific patients and drug groups.

Citing Articles

Systematic review of survey/questionnaire-based drug utilization studies in Turkiye.

Gultekin O, Haspolat N, Cicek B, Havyarimana D, Akici A, Aydin V North Clin Istanb. 2024; 11(6):525-533.

PMID: 39650312 PMC: 11622752. DOI: 10.14744/nci.2024.60252.

References
1.
Karabay O, Hosoglu S . Increased antimicrobial consumption following reimbursement reform in Turkey. J Antimicrob Chemother. 2008; 61(5):1169-71. DOI: 10.1093/jac/dkn055. View

2.
Ankrah D, Hallas J, Odei J, Asenso-Boadi F, Dsane-Selby L, Donneyong M . A review of the Ghana National Health Insurance Scheme claims database: possibilities and limits for drug utilization research. Basic Clin Pharmacol Toxicol. 2018; 124(1):18-27. DOI: 10.1111/bcpt.13136. View

3.
Linden M . Phase IV research and drug utilization observation studies. Pharmacopsychiatry. 1997; 30(1 Suppl):1-3. DOI: 10.1055/s-2007-979510. View

4.
Bachhav S, Kshirsagar N . Systematic review of drug utilization studies & the use of the drug classification system in the WHO-SEARO Region. Indian J Med Res. 2015; 142(2):120-9. PMC: 4613433. DOI: 10.4103/0971-5916.164223. View

5.
Allegaert K, Simons S, van den Anker J . Research on medication use in the neonatal intensive care unit. Expert Rev Clin Pharmacol. 2019; 12(4):343-353. DOI: 10.1080/17512433.2019.1580569. View